Catalyst Pharmaceuticals price target raised to $22 from $18 at Truist

Truist analyst Joon Lee raised the firm’s price target on Catalyst Pharmaceuticals to $22 from $18 and keeps a Buy rating on the shares. The analyst states that his recent conversations with management suggest that 2023 should be a solid production year. Lee adds that Catalyst’s Firdapse sales will likely print above 15% growth, with integration of Fycompa also seen as "relatively painless".